Discontinuation of joint sales of NEOXY® Tape 73.5 mg
transdermal overactive bladder treatment medication
Hisamitsu Pharmaceutical Co., Inc.
Asahi Kasei Pharma Corp.
Hisamitsu Pharmaceutical Co., Inc., (Head office: Tosu city, Saga Prefecture, Japan; President & CEO: Hirotaka Nakatomi; hereinafter referred to as Hisamitsu) and Asahi Kasei Pharma Corp. (Head office: Chiyoda-ku, Tokyo, Japan; President: Kazuyoshi Hori; hereinafter referred to as Asahi Kasei) reached agreement to discontinue their joint sales of NEOXY® Tape 73.5 mg, a transdermal overactive bladder treatment medication, on June 26, 2016.
While Hisamitsu and Asahi Kasei have jointly sold NEOXY® Tape 73.5 mg since June 2013, the agreement to discontinue joint sales was reached as a result of discussion between the two companies. Asahi Kasei will discontinue sales within three months from June 26, 2016, when its inventory of NEOXY® Tape 73.5 mg is depleted. After that, Hisamitsu will sell NEOXY® Tape 73.5 mg alone.
|Trade name||NEOXY® Tape 73.5 mg|
|Active pharmaceutical ingredient||Oxybutynin hydrochloride|
|Indication||Urinary urgency, frequent urination, and urge urinary incontinence caused by overactive bladders|
|Dose and Administration||Usually apply one sheet (73.5 mg of oxybutynin hydrochloride) once a day on the lower abdomen, lower back, or thigh of an adult and replace every 24 hours.|
|Packaging||70 sheets (1 sheet/pack × 70),
280 sheets (1 sheet/pack × 280)
|NHI drug price||194.80 yen/sheet|
|Date of approval for manufacturing and marketing||March 25, 2013|
|Date of initial marketing in Japan||June 27, 2013|
|Manufactured and distributed by||Hisamitsu Pharmaceutical Co., Inc.|